Dublin, Feb. 03, 2020 (GLOBE NEWSWIRE) -- The "Age-related Macular Degeneration (AMD) - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
Age-related Macular Degeneration (AMD) Pipeline Insight, 2020 outlays comprehensive insights of present clinical development scenario and growth prospects across the age-related macular degeneration market. A detailed picture of the age-related macular degeneration pipeline landscape is provided, which includes the disease overview and age-related macular degeneration treatment guidelines.
The assessment part of the report embraces in-depth age-related macular degeneration commercial assessment and clinical assessment of the age-related macular degeneration pipeline products from the pre-clinical developmental phase to the marketed phase.
In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, age-related macular degeneration collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
The report provides insights into:
- All of the companies that are developing therapies for the treatment of age-related macular degeneration (AMD) with aggregate therapies developed by each company for the same.
- Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the age-related macular degeneration (AMD) treatment.
- Age-related macular degeneration (AMD) key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of age-related macular degeneration (AMD) market.
Scope of the Report
- The age-related macular degeneration (AMD) report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for age-related macular degeneration (AMD) across the complete product development cycle, including all clinical and nonclinical stages.
- It comprises of detailed profiles of age-related macular degeneration (AMD) therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
- detailed age-related macular degeneration (AMD) research and development progress and trial details, results wherever available, are also included in the pipeline study.
- Coverage of dormant and discontinued pipeline projects along with the reasons if available across age-related macular degeneration (AMD).
Key Topics Covered
1. Report Introduction
2. Age-related Macular Degeneration (AMD)
2.1. Overview
2.2. History
2.3. Age-related Macular Degeneration (AMD) Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. Age-related Macular Degeneration (AMD) Diagnosis
2.6.1. Diagnostic Guidelines
3. Age-related Macular Degeneration (AMD) Current Treatment Patterns
3.1. Age-related Macular Degeneration (AMD) Treatment Guidelines
4. Age-related Macular Degeneration (AMD) - Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Age-related Macular Degeneration (AMD) companies collaborations, Licensing, Acquisition - Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Age-related Macular Degeneration (AMD) Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. Age-related Macular Degeneration (AMD) Acquisition Analysis
5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target
6. Age-related Macular Degeneration (AMD) Late Stage Products (Phase-III)
7. Age-related Macular Degeneration (AMD) Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Age-related Macular Degeneration (AMD) Discontinued Products
13. Age-related Macular Degeneration (AMD) Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table
14. Age-related Macular Degeneration (AMD) Key Companies
15. Age-related Macular Degeneration (AMD) Key Products
16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. Age-related Macular Degeneration (AMD) Unmet Needs
18. Age-related Macular Degeneration (AMD) Future Perspectives
19. Age-related Macular Degeneration (AMD) Analyst Review
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/fkbx6b
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.